COX-2 selective inhibitors and heart health

被引：0
|
作者：
Simon, Lee S. [3 ,4 ]
White, William B. [1 ,2 ]
机构：
[1] Univ Connecticut, Ctr Hlth, Clin Trials Unit, Farmington, CT 06030 USA
[2] Univ Connecticut, Sch Med, Calhoun Cardiol Ctr, Farmington, CT 06030 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
POSTGRADUATE MEDICINE | 2005年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
On September 30, 2004, because of an observed increased risk of serious cardiovascular (CV) events, Merck & Co, Inc, voluntarily withdrew rofecoxib from the worldwide market. The withdrawal has focused attention on the possible class effect on the cardiovascular system of the other currently available cyclooxygenase-2 (COX-2) selective inhibitors: celecoxib and valdecoxib. This review evaluates and differentiates the CV effects of COX-2 selective inhibitors through an assessment of prospective, randomized epidemiologic studies and meta-analyses.
引用
收藏
页码：7 / 20
页数：14
相关论文
共 50 条
  • [31] Selective inhibitors of COX-2 - Are they safe for the stomach?
    Giercksky, KE
    Haglund, U
    Rask-Madsen, J
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2000, 35 (11) : 1121 - 1124
  • [32] COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
    Davies, NM
    Jamali, F
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2004, 7 (03): : 332 - 336
  • [33] Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial~1
    Lars BOHLIN
    ActaPharmacologicaSinica, 2005, (08) : 926 - 933
  • [34] Cox-2 selective inhibitors induce apoptosis by both cox-2 dependent and cox-2 independent mechanisms.
    Agarwal, B
    Swaroop, P
    Protiva, P
    Chuttani, R
    Ramey, WG
    Holt, PR
    GASTROENTEROLOGY, 2000, 118 (04) : A52 - A52
  • [35] COX-2 inhibitors and risk of heart failure
    Kammerl, MC
    Debler, J
    Riegger, GA
    Krämer, BK
    LANCET, 2004, 364 (9444): : 1486 - 1487
  • [36] Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors
    Groesch, Sabine
    Maier, Thorsten Juergen
    Schiffmann, Susanne
    Geisslinger, Gerd
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (11): : 736 - 747
  • [37] NSAIDs: gastroprotection or selective COX-2 inhibitors? Reply
    Dickman, A
    Ellershaw, J
    PALLIATIVE MEDICINE, 2005, 19 (02) : 166 - 167
  • [38] SELECTIVE COX-2 INHIBITORS - Balancing risks and benefits
    Mkele, Gail
    SA PHARMACEUTICAL JOURNAL, 2009, 76 (10) : 30 - 31
  • [39] First and second generations of COX-2 selective inhibitors
    de Leval, X
    Julémont, F
    Benoit, V
    Frederich, M
    Pirotte, B
    Dogné, JM
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (06) : 597 - 601
  • [40] Selective COX-2 inhibitors as chemopreventive and therapeutic agents
    Grossman, HB
    DRUGS OF TODAY, 2003, 39 (03): : 203 - 211
12345